GlaxoSmithKline Financials

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;padding-top: 25px;;'>GP</div>
GSK -- USA Stock  

Report: 22nd of July 2020  

Understanding current and past GlaxoSmithKline PLC Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. GlaxoSmithKline PLC Interest Coverage is increasing as compared to previous years. The last year's value of Interest Coverage was reported at 146.89. The current Long Term Debt to Equity is estimated to increase to 2.70, while Earnings Before Interest Taxes and Depreciation Amortization EBITDA are estimated to decrease to under 6 B. Use fundamental data analysis to validate all available fundamentals of GlaxoSmithKline PLC to find out if markets are presently mispricing the company. We were able to break down and interpolate data for thirty-seven available reported financial drivers for GlaxoSmithKline PLC, which can be compared to its competitors. To make sure the equity is not overpriced, please check out all GlaxoSmithKline PLC financials, including its shares owned by insiders, cash and equivalents, number of employees, as well as the relationship between the price to sales and book value per share . Given that GlaxoSmithKline PLC has a price to book of 16.78 X, we strongly advise you to confirm GlaxoSmithKline PLC regular market performance to make sure the company can sustain itself down the road. Use GlaxoSmithKline PLC to protect your portfolios against small markets fluctuations. The stock experiences a somewhat bearish sentiment, but market may correct it shortly. Check odds of GlaxoSmithKline PLC to be traded at $38.71 in 30 days.

Search Fundamentals

With this module, you can analyze GlaxoSmithKline financials for your investing period. You should be able to track the changes in GlaxoSmithKline PLC individual financial statements over time to develop the understanding of its risk, liquidity, profitability, or other critical and vital indicators.

Chance of Financial Distress

GlaxoSmithKline PLC has less than 44 (%) percent chance of experiencing financial distress in the next two years of operations. The calculation of odds of distress for GlaxoSmithKline PLC stock is tightly coupled with the Probability of Bankruptcy. It complements the equity performance score by supplying investors with insight into company financials without requiring them to know too much about all of the complex accounting and financial indicators surrounding the entity. More Info

GlaxoSmithKline PLC Company Summary

GlaxoSmithKline PLC competes with Gilead Sciences, Merck, Grifols S, Johnson Johnson, and GlaxoSmithKline PLC. GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GlaxoSmithKline PLC operates under Drug Manufacturers - General classification in the United States and is traded on BATS Exchange. It employs 99437 people.
Foreign Associate  UK
Healthcare, Drug Manufacturers - General
InstrumentUSA Stock View All
ExchangeBATS Exchange
CIK Number0001131399
LocationUnited Kingdom
Business Address980 Great West
IndustryDrug Manufacturers?General
Phone(44) 20 8047 7807
CurrencyUSD - US Dollar

GlaxoSmithKline PLC Key Financial Ratios

GlaxoSmithKline PLC Key Balance Sheet Accounts

2014201520162017201820192020 (projected)
Inventories4.23 B4.72 B5.1 B5.56 B5.48 B5.95 B5.09 B
Receivables4.32 B5.27 B5.67 B5.67 B6.08 B6.87 B5.97 B
Accounts Payable2.79 B3.12 B3.6 B3.53 B3.65 B4.14 B3.48 B
Total Assets40.65 B53.45 B59.08 B56.38 B58.07 B79.69 B71.26 B
Current Assets14.68 B16.59 B16.71 B15.91 B16.93 B19.49 B19.68 B
Assets Non Current25.97 B36.86 B42.37 B40.47 B41.14 B60.2 B51.58 B
Cash and Equivalents4.34 B5.83 B4.9 B3.83 B3.87 B4.71 B4.6 B
Total Debt18.78 B16.63 B18.79 B17.09 B26.06 B30.51 B27.14 B
Debt Current2.94 B1.31 B4.13 B2.83 B5.79 B6.92 B5.47 B
Debt Non Current15.84 B15.32 B14.66 B14.26 B20.27 B23.59 B21.67 B
Shareholders Equity4.26 B5.11 B1.12 B(68 M)3.78 B11.4 B12.31 B
Inventory4.23 B4.72 B5.1 B5.56 B5.48 B5.95 B5.8 B
Investments1.52 B1.54 B1.34 B1.18 B1.64 B2.23 B2.09 B
Investments Current69 M75 M89 M78 M84 M79 M89.69 M
Total Liabilities35.72 B44.57 B54.12 B52.89 B54.39 B61.34 B56.96 B
Current Liabilities13.29 B13.42 B19 B26.57 B22.49 B24.05 B22.46 B
Tax Assets2.83 B3.08 B4.6 B4.05 B4.12 B4.36 B4.17 B
Tax Liabilities1.39 B2.94 B3.24 B2.8 B2.39 B4.63 B3.92 B

GlaxoSmithKline PLC Key Income Statement Accounts

2014201520162017201820192020 (projected)
Direct Expenses7.32 B8.85 B9.29 B10.34 B10.24 B11.86 B10 B
Consolidated Income2.83 B8.37 B1.06 B2.17 B4.05 B5.27 B4.57 B
Cost of Revenue7.32 B8.85 B9.29 B10.34 B10.24 B11.86 B11.37 B
Gross Profit15.68 B15.07 B18.6 B19.84 B20.58 B21.89 B22.54 B
Interest Expense727 M757 M736 M734 M798 M912 M935.37 M
Net Income2.76 B8.42 B912 M1.53 B3.62 B4.64 B4.14 B
Operating Expenses12.09 B4.75 B16 B15.76 B15.1 B14.93 B15.33 B
Operating Income3.6 B10.32 B2.6 B4.09 B5.48 B6.96 B6.24 B
Revenues23.01 B23.92 B27.89 B30.19 B30.82 B33.75 B33.91 B
Income Tax Expense137 M2.15 B877 M1.36 B754 M953 M1.07 B

GlaxoSmithKline PLC Key Cash Accounts

2014201520162017201820192020 (projected)
Capital Expenditure(1.15 B)(1.31 B)(1.45 B)(1.26 B)(1.18 B)(1.17 B)(1.26 B)
Net Cash Flow or Change in Cash and Cash Equivalents(1.29 B)1.5 B(1.16 B)(905 M)479 M826 M891.21 M
Net Cash Flow Business Acquisitions and Disposals118 M7.26 B47 M378 M(95 M)(3.58 B)(3.68 B)
Issuance Purchase of Equity Shares(71 M)73 M89 M56 M74 M51 M55.03 M
Issuance Repayment of Debt Securities228 M(2.44 B)130 M(990 M)8.12 B3.52 B3.79 B
Payment of Dividends and Other Cash Distributions(3.84 B)(3.87 B)(4.85 B)(3.91 B)(3.93 B)(3.95 B)(4.27 B)
Net Cash Flow from Financing(5.38 B)(7.1 B)(6.39 B)(6.38 B)(6.39 B)(1.84 B)(1.99 B)
Net Cash Flow from Investing(1.08 B)6.04 B(1.27 B)(1.44 B)(1.55 B)(5.35 B)(5.49 B)
Net Cash Flow Investment Acquisitions and Disposals123 M273 M587 M(12 M)(158 M)(188 M)(192.95 M)
Net Cash Flow from Operations6.28 B4.63 B8.11 B8.26 B9.75 B9.53 B9.6 B
Effect of Exchange Rate Changes on Cash84 M(45 M)283 M(100 M)8 M(82 M)(84.16 M)

GlaxoSmithKline Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining GlaxoSmithKline PLC's current stock value. Our valuation model uses many indicators to compare GlaxoSmithKline PLC value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across GlaxoSmithKline PLC competition to find correlations between indicators driving GlaxoSmithKline PLC's intrinsic value. More Info.
GlaxoSmithKline PLC is rated # 5 in working capital category among related companies. It is rated # 4 in short ratio category among related companies . The ratio of Working Capital to Short Ratio for GlaxoSmithKline PLC is about  1,233,463,035 . GlaxoSmithKline PLC Working Capital is decreasing as compared to previous years. The last year's value of Working Capital was reported at -4,559,000,000

GlaxoSmithKline PLC Systematic Risk

The output start index for this execution was eighteen with a total number of output elements of fourty-three. The Beta measures systematic risk based on how returns on GlaxoSmithKline PLC correlated with the market. If Beta is less than 0 GlaxoSmithKline PLC generally moves in the opposite direction as compared to the market. If GlaxoSmithKline PLC Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one GlaxoSmithKline PLC is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of GlaxoSmithKline PLC is generally in the same direction as the market. If Beta > 1 GlaxoSmithKline PLC moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.

About GlaxoSmithKline PLC Financials

What exactly are GlaxoSmithKline PLC Financials? Typically, a company's financial statements are the reports that show the financial position of the company. There are three primary documents that fall into the category of financial statements. These documents include GlaxoSmithKline PLC income statement, its balance sheet, and the statement of cash flows. Potential GlaxoSmithKline PLC investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although GlaxoSmithKline PLC investors may use each financial statement separately, they are all related. The changes in GlaxoSmithKline PLC's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on GlaxoSmithKline PLC's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Receivables5.67 B6.08 B6.87 B5.97 B
Inventories5.56 B5.48 B5.95 B5.09 B

GlaxoSmithKline PLC July 12, 2020 Opportunity Range

Along with financial statement analysis, the daily predictive indicators of GlaxoSmithKline PLC help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of GlaxoSmithKline PLC. We use our internally-developed statistical techniques to arrive at the intrinsic value of GlaxoSmithKline PLC based on widely used predictive technical indicators. In general, we focus on analyzing GlaxoSmithKline PLC stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build GlaxoSmithKline PLC's daily price indicators and compare them against related drivers.
Downside Deviation1.86
Information Ratio(0.05)
Maximum Drawdown10.16
Value At Risk(2.10)
Potential Upside2.1
Please check Risk vs Return Analysis. Please also try Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page